Reliance Of India Seeks To Be Leader In Biotech Generics
This article was originally published in PharmAsia News
Executive Summary
India's Reliance Life Sciences plans to be a major player in the generic versions of biotechnology drugs, according to President and CEO K.V. Subramanian